Navigation Links
Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use
Date:2/18/2009

Nearly 150,000 PCIs Were Performed on AMI Patients in 2008, According to Millennium Research Group

WALTHAM, Mass., Feb. 18 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Interventional Cardiology Devices 2009 report, the use of drug-eluting stents will continue to climb steadily through 2013, driven in large part by the adoption of primary percutaneous coronary intervention (PCI) in Acute Myocardial Infarction (AMI) patients, who accounted for nearly 150,000 PCIs in the US in 2008.

In the past, primary PCI--defined as a PCI performed within 24 hours of the onset of symptoms--was mostly limited to facilities that had surgical back-up present. Studies have shown, however, that AMI patients who undergo primary PCI have improved outcomes over thrombolytics, even without surgical back-up. Experts are now trying to reduce the time it takes to get patients to a cath lab -- in some cases bypassing the emergency room -- which will drive primary PCI adoption and support DES use in AMI patients.

Furthermore, a number of clinical trials in 2007 and 2008 released positive clinical data, which showed that ST-elevation myocardial infarction (STEMI) patients who receive aspiration with stenting have better blood flow, enhanced myocardial function, and lower mortality rates than patients who received angioplasty with stenting or direct stenting.

"The TAPAS trial indicated that STEMI patients treated with aspiration prior to stenting had over 30% lower mortality in the following year compared to those who had angioplasty-with-stent procedures," says Stephanie LaBelle, Senior Analyst at MRG. "As a result, the portion of primary PCIs using aspiration rather than predilation prior to stenting will grow in AMI patients through 2013."

MRG's US Markets for Interventional Cardiology Devices 2009 report provides coverage of key industry trends, including new segments on the treatment of AMI patients and bifurcated lesions, as well as the launch of new devices from Abbott Vascular, Boston Scientific, and Medtronic. Additional leading competitors covered include AngioScore, Cordis, C.R. Bard, Cook Medical, ev3, St. Jude Medical, Terumo Medical, and many more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
2. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
3. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
4. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
5. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
8. Merck Seronos Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinsons Disease in a Phase III Pivotal Trial
9. First U.S. Patients Enrolled in the REALISM Continued Access Study
10. Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
11. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
Breaking Medicine News(10 mins):